


# Stereotactic body RT promising for low-, intermediate-risk PCa

5 March 2019



incidence of acute grade 3 or higher genitourinary toxic events and gastrointestinal toxic events was 0.6 and 0.09 percent, respectively. For late grade 3 or higher genitourinary toxic events, the seven-year cumulative incidence was 2.4 percent; it was 0.4 percent for gastrointestinal toxic events.

"These data suggest that stereotactic body radiotherapy is an appropriate definitive treatment modality for low-risk and intermediate-risk prostate cancer," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

**More information:** [Abstract/Full Text](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

(HealthDay)—In men with low-risk and intermediate-risk prostate cancer, stereotactic body radiotherapy is associated with low rates of severe toxic events and high rates of biochemical control, according to a study published online Feb. 8 in *JAMA Network Open*.

Amar U. Kishan, M.D., from the University of California in Los Angeles, and colleagues assessed long-term outcomes after stereotactic body [radiotherapy](#) for [low-risk](#) and intermediate-risk prostate cancer. A total of 2,142 men (mean age, 67.9 years) who participated in phase 2 [clinical trials](#) between 2000 and 2012 were followed from Jan. 1, 2013, to May 1, 2018 (median follow-up, 6.9 years).

The researchers found that the seven-year cumulative rates of biochemical recurrence were 4.5 percent for low-risk disease, 8.6 percent for favorable intermediate-risk disease, 14.9 percent for unfavorable intermediate-risk disease, and 10.2 percent for all intermediate-risk [disease](#). The crude

APA citation: Stereotactic body RT promising for low-, intermediate-risk PCa (2019, March 5) retrieved 8 December 2021 from <https://medicalxpress.com/news/2019-03-stereotactic-body-rt-low-intermediate-risk.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*